Appyea - APYP STOCK NEWS

AppYea's Chairman Bary Molchadsky has converted approximately $140,000 of his debt into company warrants, with a strike price of $0.07 per share, reflecting a 250% premium over the current market price. This move demonstrates his confidence in the company's prospects. AppYea has recently started commercial deliveries of its AppySleep product in the U.S. and launched a new direct sales website and an Amazon store. The AppySleep wristband, a smart wearable for monitoring and treating sleep apnea and snoring, integrates with a smartphone app to improve sleep quality.

AppYea, Inc. (APYP) launches AppySleep smart wristband on Amazon, fulfilling pre-orders and entering the $17.9 billion Sleep Tech Device Market. The device helps diagnose snoring and sleep apnea, with a proprietary AI-driven solution. AppYea aims to disrupt the sleep apnea market with its innovative design and user-centric approach.

AppYea, Inc. (APYP) announces the commercial launch of AppySleep, an innovative wearable monitoring solution designed to treat sleep apnea and snoring. The product is now available for purchase online and is set to be sold in stores as part of the second phase of its rollout.

AppYea Inc. (APYP) provided a letter to shareholders from CEO Adi Shemer, highlighting the company's progress in 2023. The company is focused on developing accurate wearable monitoring solutions for sleep apnea and snoring. AppYea is gearing up to enter the commercial phase and begin marketing its products in the United States and globally. The company's patent portfolio includes snoring detection, sleep apnea diagnosis, and sleep quality diagnosis through voice analysis. AppYea has made technological advancements, expanded its intellectual property, achieved manufacturing success, secured strategic partnerships, expanded its e-commerce presence, enhanced leadership, strengthened its financial position, and is anticipating product expansion in 2024.

SleepX, a subsidiary of AppYea Inc., has been granted a patent for sleep apnea diagnostics, with the market projected to reach $9.27 billion by 2033.

AppYea Inc. has announced an equity financing transaction with strategic investors, which is expected to accelerate the commercial launch of its DreamIT biofeedback snoring treatment wristband. The financing will also support regulatory activities for the DreamIT PRO wristband and SleepX PRO app for sleep apnea treatment. The strategic investors will purchase outstanding Company notes, extend their maturity period, and amend the conversion price. The total investment, including equity investment and repurchase of outstanding notes and preferred shares, is expected to reach $4 million. The transaction will streamline the company's capital structure and eliminate all company debt.

AppYea Inc. announced the appointment of Adi Shemer as Chief Executive Officer. Shemer has over 20 years of experience in revitalizing and developing international markets for companies. He will focus on advancing regulatory approval and commercialization of the company's sleep apnea and snoring devices. The combined markets for these devices have a $10 billion addressable market.

AppYea Inc. (OTCQB:APYP) announced the immediate addition of Adi Shemer to its advisory board. Shemer has a robust background in operations management within the medical device sector, having held senior executive positions, including CEO at TR bike Ltd. and Tzora Active Systems Ltd. He aims to enhance the production and distribution of AppYea's innovative wearable device, DreamIT, designed to improve sleep quality. The company's focus remains on commercialization, backed by a strong IP portfolio and positive market feedback. This strategic move comes as AppYea transitions from development to commercial operations, indicating growth potential in the sleep health market.

AppYea Inc. (OTCQB:APYP) has appointed Ron Mekler as an independent director and Chair of the Audit Committee, effective immediately. This strategic move aims to enhance the company's board and management using Mekler's extensive experience in finance and healthcare. Mekler previously served as CFO at Clalit Health Services, Israel's largest health organization, and has a robust background in various industries. He expressed confidence in AppYea's potential and its innovative sleep monitoring solutions, which are protected by multiple patents. This leadership change is expected to strengthen the firm's market position and attract partnerships.